Victory Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $96.4M | Buy |
731,609
+607,049
| +487% | +$80.5M | 0.06% | 325 |
|
|
2025
Q4 | $17.7M | Sell |
124,560
-285
| -0.2% | -$41.3K | 0.01% | 899 |
|
|
2025
Q3 | $17.5M | Buy |
124,845
+31,981
| +34% | +$4.33M | 0.01% | 929 |
|
|
2025
Q2 | $11.7M | Buy |
92,864
+955
| +1% | +$110K | 0.01% | 1061 |
|
|
2025
Q1 | $10.2M | Sell |
91,909
-97,987
| -52% | -$12.4M | 0.01% | 1034 |
|
|
2024
Q4 | $25.9M | Sell |
189,896
-14,309
| -7% | -$1.77M | 0.03% | 744 |
|
|
2024
Q3 | $23.5M | Buy |
204,205
+66,662
| +48% | +$9.14M | 0.02% | 788 |
|
|
2024
Q2 | $18.9M | Buy |
137,543
+1,676
| +1% | +$230K | 0.02% | 831 |
|
|
2024
Q1 | $18.7M | Buy |
135,867
+18,646
| +16% | +$2.55M | 0.02% | 843 |
|
|
2023
Q4 | $15.4M | Buy |
117,221
+47,389
| +68% | +$5.45M | 0.02% | 874 |
|
|
2023
Q3 | $7.86M | Buy |
69,832
+463
| +0.7% | +$48.8K | 0.01% | 1106 |
|
|
2023
Q2 | $6.54M | Sell |
69,369
-11,024
| -14% | -$1.08M | 0.01% | 1151 |
|
|
2023
Q1 | $8.14M | Sell |
80,393
-32,945
| -29% | -$3.43M | 0.01% | 1095 |
|
|
2022
Q4 | $13.5M | Buy |
113,338
+15,478
| +16% | +$1.81M | 0.02% | 921 |
|
|
2022
Q3 | $10.4M | Buy |
97,860
+12,535
| +15% | +$1.27M | 0.01% | 1055 |
|
|
2022
Q2 | $8.32M | Sell |
85,325
-695
| -0.8% | -$64.1K | 0.01% | 1124 |
|
|
2022
Q1 | $7.74M | Buy |
86,020
+69,412
| +418% | +$5.88M | 0.01% | 1192 |
|
|
2021
Q4 | $1.42M | Sell |
16,608
-4,238
| -20% | -$390K | ﹤0.01% | 1678 |
|
|
2021
Q3 | $2M | Sell |
20,846
-18,334
| -47% | -$1.73M | ﹤0.01% | 1605 |
|
|
2021
Q2 | $3.81M | Sell |
39,180
-1,985
| -5% | -$190K | ﹤0.01% | 1436 |
|
|
2021
Q1 | $4M | Sell |
41,165
-342,211
| -89% | -$35.9M | ﹤0.01% | 1418 |
|
|
2020
Q4 | $36.7M | Sell |
383,376
-318,735
| -45% | -$30.8M | 0.04% | 631 |
|
|
2020
Q3 | $67.5M | Buy |
702,111
+59,279
| +9% | +$6.86M | 0.09% | 330 |
|
|
2020
Q2 | $78.4M | Sell |
642,832
-503,570
| -44% | -$55.6M | 0.11% | 267 |
|
|
2020
Q1 | $99.2M | Buy |
1,146,402
+506,701
| +79% | +$49.6M | 0.08% | 341 |
|
|
2019
Q4 | $68.8M | Buy |
639,701
+199,705
| +45% | +$20.9M | 0.08% | 355 |
|
|
2019
Q3 | $39.6M | Buy |
439,996
+172,526
| +65% | +$16.1M | 0.05% | 536 |
|
|
2019
Q2 | $22.6M | Sell |
267,470
-268,630
| -50% | -$22.1M | 0.05% | 572 |
|
|
2019
Q1 | $47.2M | Sell |
536,100
-17,085
| -3% | -$1.43M | 0.11% | 293 |
|
|
2018
Q4 | $39.5M | Sell |
553,185
-51,950
| -9% | -$4.98M | 0.1% | 312 |
|
|
2018
Q3 | $74.4M | Buy |
605,135
+228,163
| +61% | +$25.9M | 0.15% | 179 |
|
|
2018
Q2 | $37M | Sell |
376,972
-192,628
| -34% | -$17.2M | 0.08% | 417 |
|
|
2018
Q1 | $47.2M | Buy |
569,600
+568,940
| +86,203% | +$48M | 0.1% | 314 |
|
|
2017
Q4 | $51K | Hold |
660
| – | – | ﹤0.01% | 1742 |
|
|
2017
Q3 | $40K | Hold |
660
| – | – | ﹤0.01% | 1754 |
|
|
2017
Q2 | $30K | Buy |
660
+11
| +2% | +$534 | ﹤0.01% | 1757 |
|
|
2017
Q1 | $28K | Sell |
649
-16,400
| -96% | -$703K | ﹤0.01% | 1750 |
|
|
2016
Q4 | $660K | Buy |
17,049
+36
| +0.2% | +$1.63K | ﹤0.01% | 1225 |
|
|
2016
Q3 | $861K | Buy |
17,013
+16,441
| +2,874% | +$819K | ﹤0.01% | 1089 |
|
|
2016
Q2 | $26K | Buy |
572
+74
| +15% | +$3.41K | ﹤0.01% | 1585 |
|
|
2016
Q1 | $20K | Buy |
498
+35
| +8% | +$1.39K | ﹤0.01% | 1611 |
|
|
2015
Q4 | $26K | Buy |
463
+25
| +6% | +$1.27K | ﹤0.01% | 1627 |
|
|
2015
Q3 | $17K | Buy |
438
+34
| +8% | +$1.64K | ﹤0.01% | 1589 |
|
|
2015
Q2 | $19K | Buy |
+404
| New | +$17.1K | ﹤0.01% | 1598 |
|
Other funds holding NBIX
VPM
VCM
Victory Capital Management's NBIX Position: Q1 2026 in Review
Victory Capital Management increased its Neurocrine Biosciences (NBIX) stake by 487% in Q1 2026, buying an estimated $80.5M and bringing the position to 731,609 shares worth $96.4M. The position accounts for 0.06% of the portfolio, ranked #325.
Victory Capital Management first reported a position in NBIX in Q2 2015 and has held it in 44 quarters since. The position peaked at $99.2M in Q1 2020. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Victory Capital Management held 731,609 shares of Neurocrine Biosciences worth $96.4M as of Q1 2026.
- Victory Capital Management bought 607,049 Neurocrine Biosciences shares in Q1 2026, an estimated $80.5M.
- Neurocrine Biosciences made up 0.06% of Victory Capital Management's portfolio in Q1 2026, its #325 holding.
- Victory Capital Management first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 44 quarters since.
- Victory Capital Management's Neurocrine Biosciences position peaked at $99.2M in Q1 2020.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.